Made available in DSpace on 2016-02-05T18:29:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2015-06-26. Added 1 bitstream(s) on 2016-02-05T18:33:01Z : No. of bitstreams: 1 000856445_20160727.pdf: 977688 bytes, checksum: ae5df9cf2d16b4bea468e1dbcde7a56b (MD5) Bitstreams deleted on 2016-07-29T12:53:58Z: 000856445_20160727.pdf,. Added 1 bitstream(s) on 2016-07-29T12:54:51Z : No. of bitstreams: 1 000856445.pdf: 2373925 bytes, checksum: 84feea00940d3e8928d739626e476bca (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A hipertensão arterial sistêmica em idosos é uma condição clínica muito prevalente e que nos últimos anos, principalmente, vem apresentando aumento no número de casos, acometendo 55% dos idosos brasileiros (≥ 65 anos). É uma doença que demanda altos custos médicos e socioeconômicos, decorrentes de suas complicações, principalmente quando o paciente não adere ao tratamento, levando a um problema crítico de saúde pública. A atenção farmacêutica pode ajudar na adesão à terapia, por ser uma prática com interação entre o farmacêutico e paciente, a qual detecta os problemas relacionados aos medicamentos para auxiliar o paciente a ter uma farmacoterapia racional. Neste contexto, políticas de saúde como a Estratégia Saúde da Família com adição dos serviços de seguimento farmacoterapêutico contribuem para a prevenção da doença e melhora os cuidados da população idosa com hipertensão. Este estudo tratou-se de um ensaio clínico controlado, aleatorizado e prospectivo cujo objetivo foi avaliar e realizar o seguimento farmacoterapêutico em pacientes idosos com hipertensão arterial sistêmica vinculados a uma unidade de Estratégia Saúde da Família de Araraquara-SP. Teve como desfecho primário: aplicar o modelo de seguimento farmacoterapêutico em idosos com hipertensão arterial sistêmica e avaliar sua aplicabilidade no sistema público de saúde em nível de Atenção Básica, especificamente na Estratégia Saúde da Família. Como desfecho secundário: adequar os parâmetros clínicos e antropométricos dos pacientes às faixas de normalidade utilizando como base os valores descritos nas diretrizes brasileiras, além de promover nos pacientes aumento da adesão ao tratamento medicamentoso, autoconhecimento sobre a doença e melhorar a qualidade de vida dos pacientes. O presente estudo foi realizado com 62 usuários cadastrados na Estratégia Saúde da Família, divididos em dois grupos: controle (31) e... / Systemic arterial hypertension in the elderly people is a very common clinical condition, which mainly in recent years has been showing an increase in the number of cases, affecting 55% of Brazilian elderly (≥ 65 years old). It is a disease, which demands high medical and socioeconomic costs arising from its complications, especially when the patient does not adhere to treatment, leading to a critical public health problem. The pharmaceutical care can help in adherence to therapy, as it is a practice with interaction between the pharmacist and patient, which detects problems related to drugs in order to help patients to have a rational pharmacotherapy. In this context, health policies such as the Family Health Strategy in addition to the pharmacotherapeutic follow-up services contribute to the disease prevention and improve the care of elderly people with hypertension. This study was a controlled randomized, prospective clinical trial aimed to evaluate and carry out the pharmacotherapeutic follow-up in elderly patients with hypertension linked to a Family Health Strategy Unit of Araraquara-SP. It had as the primary endpoint: implementing the pharmacotherapeutic follow-up model in elderly patients with systemic arterial hypertension and evaluating its effectiveness in the public health system at the level of Primary Care, specifically in the Family Health Strategy. And as a secondary endpoint: adequating clinical and anthropometric parameters of patients to the ranges using the values described in the Brazilian guidelines as a basis, besides increasing the patients adherence to drug therapy, self-knowledge about the disease and improving the patients quality of life. This study was conducted with 62 registered users in the Family Health Strategy, divided into two groups: control (31) and intervention (31). It was used pharmaceutical care method based on Pharmacist's Workup of Drug Therapy to carry out the pharmacotherapeutic follow-up, ...

Made available in DSpace on 2018-07-27T18:26:16Z (GMT). No. of bitstreams: 0 Previous issue date: 2015-06-26. Added 1 bitstream(s) on 2018-07-27T18:30:41Z : No. of bitstreams: 1 000874221.pdf: 2053327 bytes, checksum: 17bb6684f468a31077adcf490c57f204 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Metabolic Syndrome is a cluster of risk factors for developing cardiovascular disease and type 2 diabetes. In Brazil, studies have reported that prevalence of the metabolic syndrome varies between 30% and 45% of the population. This scenario demonstrates the need to develop new health care approaches, especially in primary care to prevent, detect and treat complications of metabolic syndrome. The objective of this study was to develop and accomplish a pharmaceutical care model to elderly patients with metabolic syndrome users of the Family Health Strategy (FHS) in order to monitor the biochemical and physiological parameters, and prevent comorbidities. In this prospective clinical study conducted between November 2013 and June 2014, 55 elderly were investigated and divided into two groups. The control group (28) received the traditional care while the intervention group (27), in addition to the traditional care, had pharmaceutical care. Drug Related Problems (DRPs) were evaluated before and after pharmaceutical care. Adherence to drug therapy, blood pressure, cholesterol, triglycerides, fasting glucose and waist circumference were also evaluated. The meetings with patient took place monthly over six months. In the intervention group, systolic blood pressure was significantly reduced by 13 mmHg and diastolic by 6 mmHg and abdominal circumference decreased from 109,3 cm to 106,9 cm for women and 108,6 cm to 106 cm in men (p <0.05). Total cholesterol did not change significantly in IG, however increased in CG from 183 mg / dL to 211 mg / dL (p <0.05). At the beginning of follow-up, only 10 patients were considered adherent to drug therapy and at the end, 17 adhered to therapy (p<0,05). The most prevalent DRPs were lack of adherence to treatment and need of additional medication. It was detected 68 Drug Related Problems, of which 50 (74%) were ...

Orientador : Jean Leandro dos Santos / Banca: José Luiz Riani Costa / Banca: Marcelo Tadeu Marin / Resumo: A hipertensão arterial sistêmica em idosos é uma condição clínica muito prevalente e que nos últimos anos, principalmente, vem apresentando aumento no número de casos, acometendo 55% dos idosos brasileiros (≥ 65 anos). É uma doença que demanda altos custos médicos e socioeconômicos, decorrentes de suas complicações, principalmente quando o paciente não adere ao tratamento, levando a um problema crítico de saúde pública. A atenção farmacêutica pode ajudar na adesão à terapia, por ser uma prática com interação entre o farmacêutico e paciente, a qual detecta os problemas relacionados aos medicamentos para auxiliar o paciente a ter uma farmacoterapia racional. Neste contexto, políticas de saúde como a Estratégia Saúde da Família com adição dos serviços de seguimento farmacoterapêutico contribuem para a prevenção da doença e melhora os cuidados da população idosa com hipertensão. Este estudo tratou-se de um ensaio clínico controlado, aleatorizado e prospectivo cujo objetivo foi avaliar e realizar o seguimento farmacoterapêutico em pacientes idosos com hipertensão arterial sistêmica vinculados a uma unidade de Estratégia Saúde da Família de Araraquara-SP. Teve como desfecho primário: aplicar o modelo de seguimento farmacoterapêutico em idosos com hipertensão arterial sistêmica e avaliar sua aplicabilidade no sistema público de saúde em nível de Atenção Básica, especificamente na Estratégia Saúde da Família. Como desfecho secundário: adequar os parâmetros clínicos e antropométricos dos pacientes às faixas de normalidade utilizando como base os valores descritos nas diretrizes brasileiras, além de promover nos pacientes aumento da adesão ao tratamento medicamentoso, autoconhecimento sobre a doença e melhorar a qualidade de vida dos pacientes. O presente estudo foi realizado com 62 usuários cadastrados na Estratégia Saúde da Família, divididos em dois grupos: controle (31) e... / Abstract: Systemic arterial hypertension in the elderly people is a very common clinical condition, which mainly in recent years has been showing an increase in the number of cases, affecting 55% of Brazilian elderly (≥ 65 years old). It is a disease, which demands high medical and socioeconomic costs arising from its complications, especially when the patient does not adhere to treatment, leading to a critical public health problem. The pharmaceutical care can help in adherence to therapy, as it is a practice with interaction between the pharmacist and patient, which detects problems related to drugs in order to help patients to have a rational pharmacotherapy. In this context, health policies such as the Family Health Strategy in addition to the pharmacotherapeutic follow-up services contribute to the disease prevention and improve the care of elderly people with hypertension. This study was a controlled randomized, prospective clinical trial aimed to evaluate and carry out the pharmacotherapeutic follow-up in elderly patients with hypertension linked to a Family Health Strategy Unit of Araraquara-SP. It had as the primary endpoint: implementing the pharmacotherapeutic follow-up model in elderly patients with systemic arterial hypertension and evaluating its effectiveness in the public health system at the level of Primary Care, specifically in the Family Health Strategy. And as a secondary endpoint: adequating clinical and anthropometric parameters of patients to the ranges using the values described in the Brazilian guidelines as a basis, besides increasing the patients adherence to drug therapy, self-knowledge about the disease and improving the patients quality of life. This study was conducted with 62 registered users in the Family Health Strategy, divided into two groups: control (31) and intervention (31). It was used pharmaceutical care method based on Pharmacist's Workup of Drug Therapy to carry out the pharmacotherapeutic follow-up, ... / Mestre

Orientador: Jean Leandro dos Santos / Banca: José Luiz Riani Costa / Banca: Ricardo Radhiguieri Rascado / Resumo:A Síndrome Metabólica é um conjunto de fatores de risco para o desenvolvimento de doenças cardiovasculares e diabetes mellitus 2. No Brasil, estudos relatam que a prevalência de síndrome metabólica varia entre 30% e 45% da população. Tal panorama demonstra a necessidade de desenvolver novas abordagens de cuidado em saúde, principalmente na Atenção Básica, para prevenir, detectar e tratar complicações decorrentes deste problema. O objetivo deste trabalho foi desenvolver e aplicar um modelo de acompanhamento farmacoterapêutico em pacientes idosos diagnosticados com síndrome metabólica e usuários da Estratégia Saúde da Família (ESF), a fim de controlar os parâmetros bioquímicos e fisiológicos, e prevenir o aparecimento de comorbidades. Neste estudo clínico prospectivo, realizado entre novembro de 2013 e junho de 2014, foram acompanhados 55 idosos divididos em dois grupos. O grupo controle (28) recebeu o cuidado da equipe da ESF enquanto o grupo intervenção (27), além da ESF, teve acompanhamento farmacêutico. Foram avaliados antes e depois do seguimento farmacoterapêutico os Problemas Relacionados com Medicamento (PRM), a adesão à terapia medicamentosa, a pressão arterial, o colesterol total, os triglicérides, a glicemia em jejum e a circunferência abdominal. Os encontros com o usuário se deram ao longo de seis meses. No grupo intervenção, a pressão arterial sistólica e a diastólica sofreram redução significativa: -13 mmHg e -6mmHg respectivamente; a circunferência abdominal reduziu de 109,3 cm para 106,9 cm nas mulheres e de 108,6 cm para 106 cm nos homens (p<0,05). O colesterol total não sofreu alteração significativa no GI, entretanto aumentou no GC de 183 mg/dL para 211 mg/dL (p<0,05). No início do acompanhamento, apenas 10 pacientes do GI apresentavam adesão à terapia medicamentosa e... / Abstract: Metabolic Syndrome is a cluster of risk factors for developing cardiovascular disease and type 2 diabetes. In Brazil, studies have reported that prevalence of the metabolic syndrome varies between 30% and 45% of the population. This scenario demonstrates the need to develop new health care approaches, especially in primary care to prevent, detect and treat complications of metabolic syndrome. The objective of this study was to develop and accomplish a pharmaceutical care model to elderly patients with metabolic syndrome users of the Family Health Strategy (FHS) in order to monitor the biochemical and physiological parameters, and prevent comorbidities. In this prospective clinical study conducted between November 2013 and June 2014, 55 elderly were investigated and divided into two groups. The control group (28) received the traditional care while the intervention group (27), in addition to the traditional care, had pharmaceutical care. Drug Related Problems (DRPs) were evaluated before and after pharmaceutical care. Adherence to drug therapy, blood pressure, cholesterol, triglycerides, fasting glucose and waist circumference were also evaluated. The meetings with patient took place monthly over six months. In the intervention group, systolic blood pressure was significantly reduced by 13 mmHg and diastolic by 6 mmHg and abdominal circumference decreased from 109,3 cm to 106,9 cm for women and 108,6 cm to 106 cm in men (p <0.05). Total cholesterol did not change significantly in IG, however increased in CG from 183 mg / dL to 211 mg / dL (p <0.05). At the beginning of follow-up, only 10 patients were considered adherent to drug therapy and at the end, 17 adhered to therapy (p<0,05). The most prevalent DRPs were lack of adherence to treatment and need of additional medication. It was detected 68 Drug Related Problems, of which 50 (74%) were ... / Mestre